• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

兰替洛尔®在猫体内的耐受性和疗效。

Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in cats.

机构信息

Bayer Animal Health GmbH, Global Drug Discovery & Development, Building 6700, 51368 Leverkusen, Germany.

出版信息

BMC Vet Res. 2012 Feb 6;8:14. doi: 10.1186/1746-6148-8-14.

DOI:10.1186/1746-6148-8-14
PMID:22305206
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3395877/
Abstract

BACKGROUND

Tolerability and efficacy of the intestinal phosphate binder Lantharenol® (lanthanum carbonate octahydrate) were tested in two prospective, randomized and negative controlled laboratory studies with healthy adult cats fed commercial maintenance diets non-restricted in phosphorus. In the first study, the maximal tolerated dose was determined. Starting from a dose of 0.125 g/kg body weight mixed with the daily feed ration, the dose of Lantharenol® was doubled every other week until signs of intolerability were observed (N=10 cats compared to 5 untreated controls). In the second study, the effects of feed supplementation for two weeks with approximately 2, 6, and 20% of the maximal tolerated dose on phosphorus excretion patterns and balance were assessed (N=8 cats per group).

RESULTS

Lantharenol® was found to be safe and well tolerated up to the dose of 1 g/kg bodyweight, corresponding to a concentration of 84 g Lantharenol®/kg complete feed, defined as dry matter with a standard moisture content of 12%. Feed supplementation for two weeks with approximately 2-20% of this dosage (i.e., 1.6, 4.8, and 16 g/kg complete feed) resulted in a shift from urinary to faecal phosphorus excretion. Apparent phosphorus digestibility was dose-dependently reduced compared to the control group fed with diet only (N=8).

CONCLUSIONS

The feed additive was well accepted and tolerated by all cats. Therefore, Lantharenol® presents a well tolerated and efficacious option to individually tailor restriction of dietary phosphorus as indicated, for instance, in feline chronic kidney disease.

摘要

背景

在两项前瞻性、随机和阴性对照的实验室研究中,用商业维持饲料喂养非限制磷的健康成年猫,测试了肠道磷结合剂 Lantharenol®(八水合碳酸镧)的耐受性和疗效。在第一项研究中,确定了最大耐受剂量。从 0.125 g/kg 体重的剂量与每日饲料混合开始,每隔一周将 Lantharenol®的剂量增加一倍,直到出现不耐受迹象(N=10 只猫,与 5 只未治疗的对照猫相比)。在第二项研究中,评估了两周内用大约 2%、6%和 20%的最大耐受剂量补充饲料对磷排泄模式和平衡的影响(每组 N=8 只猫)。

结果

发现 Lantharenol®在高达 1 g/kg 体重的剂量下是安全且耐受良好的,相当于 84 g Lantharenol®/kg 全价饲料,定义为标准水分含量为 12%的干物质。两周内用大约 2-20%的剂量(即 1.6、4.8 和 16 g/kg 全价饲料)补充饲料会导致磷从尿中转移到粪便中排泄。与仅用饮食喂养的对照组相比,表观磷消化率呈剂量依赖性降低(N=8)。

结论

所有猫都很好地接受和耐受了这种饲料添加剂。因此,Lantharenol®是一种耐受良好且有效的选择,可以根据需要个体化限制饮食中的磷,例如在猫慢性肾病中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce9/3395877/3d5d01920780/1746-6148-8-14-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce9/3395877/0ad6eeec1cbc/1746-6148-8-14-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce9/3395877/3d5d01920780/1746-6148-8-14-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce9/3395877/0ad6eeec1cbc/1746-6148-8-14-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ce9/3395877/3d5d01920780/1746-6148-8-14-2.jpg

相似文献

1
Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in cats.兰替洛尔®在猫体内的耐受性和疗效。
BMC Vet Res. 2012 Feb 6;8:14. doi: 10.1186/1746-6148-8-14.
2
Efficacy, acceptability and tolerability of the new oral phosphate binder Lenziaren® in healthy cats fed a standard diet.新型口服磷结合剂 Lenziaren® 在正常饮食喂养的健康猫中的疗效、可接受性和耐受性。
BMC Vet Res. 2014 Oct 28;10:258. doi: 10.1186/s12917-014-0258-8.
3
Efficacy and acceptability of the new oral phosphate binder Lenziaren(®) in healthy cats fed a renal diet.
J Vet Pharmacol Ther. 2015 Jun;38(3):278-89. doi: 10.1111/jvp.12173. Epub 2014 Nov 3.
4
Assessment of the application for renewal of authorisation of Lantharenol (lanthanum carbonate octahydrate) for cats.猫用碳酸镧八水合物(Lantharenol)续期授权申请的评估。
EFSA J. 2019 Jan 11;17(1):e05542. doi: 10.2903/j.efsa.2019.5542. eCollection 2019 Jan.
5
Renal phosphorus excretion in adult healthy cats after the intake of high phosphorus diets with either calcium monophosphate or sodium monophosphate.成年健康猫摄入含磷酸一钙或磷酸一钠的高磷饮食后的肾脏磷排泄情况。
J Anim Physiol Anim Nutr (Berl). 2018 Dec;102(6):1759-1765. doi: 10.1111/jpn.12982. Epub 2018 Aug 27.
6
Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.碳酸镧降低3期和4期慢性肾脏病患者的磷负荷:一项随机试验。
Clin J Am Soc Nephrol. 2009 Jan;4(1):178-85. doi: 10.2215/CJN.02830608. Epub 2008 Dec 3.
7
A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.一项关于新型磷结合剂碳酸镧治疗接受血液透析患者安全性的长期开放标签扩展研究。
Curr Med Res Opin. 2005 May;21(5):657-64. doi: 10.1185/030079905X41453.
8
Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.碳酸镧(福斯利诺)治疗终末期肾病高磷血症患者的疗效和耐受性。
Clin Nephrol. 2005 Jun;63(6):461-70. doi: 10.5414/cnp63461.
9
Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.碳酸镧对接受血液透析的慢性肾衰竭患者降低血清磷水平的疗效及安全性。
Clin Nephrol. 2004 Sep;62(3):193-201. doi: 10.5414/cnp62193.
10
Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.一项随机、双盲、安慰剂对照、剂量滴定的III期研究,评估碳酸镧(一种用于治疗高磷血症的新型磷结合剂)的疗效和耐受性。
Am J Kidney Dis. 2003 Jul;42(1):96-107. doi: 10.1016/s0272-6386(03)00554-7.

引用本文的文献

1
Assessment of the application for renewal of authorisation of Lantharenol (lanthanum carbonate octahydrate) for cats.猫用碳酸镧八水合物(Lantharenol)续期授权申请的评估。
EFSA J. 2019 Jan 11;17(1):e05542. doi: 10.2903/j.efsa.2019.5542. eCollection 2019 Jan.
2
ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease.国际猫科医学协会关于猫慢性肾病诊断与管理的共识指南
J Feline Med Surg. 2016 Mar;18(3):219-39. doi: 10.1177/1098612X16631234.
3
Comparative palatability of five supplements designed for cats suffering from chronic renal disease.

本文引用的文献

1
Treatment options for hyperphosphatemia in feline CKD: what's out there?猫慢性肾病高磷血症的治疗选择:有哪些方法?
J Feline Med Surg. 2009 Nov;11(11):913-24. doi: 10.1016/j.jfms.2009.09.012.
2
Aluminum toxicity following administration of aluminum-based phosphate binders in 2 dogs with renal failure.2只肾衰竭犬使用铝基磷酸盐结合剂后出现铝中毒。
J Vet Intern Med. 2008 Nov-Dec;22(6):1432-5. doi: 10.1111/j.1939-1676.2008.0206.x.
3
Survival in cats with naturally occurring chronic kidney disease (2000-2002).自然发生的慢性肾病猫的生存情况(2000 - 2002年)
五种专为患有慢性肾病的猫设计的补品的适口性比较。
Ir Vet J. 2014 May 19;67(1):10. doi: 10.1186/2046-0481-67-10. eCollection 2014.
4
Feline CKD: Current therapies - what is achievable?猫慢性肾病:当前的治疗方法——能取得什么成效?
J Feline Med Surg. 2013 Sep;15 Suppl 1(1 Suppl):29-44. doi: 10.1177/1098612X13495241.
J Vet Intern Med. 2008 Sep-Oct;22(5):1111-7. doi: 10.1111/j.1939-1676.2008.0163.x. Epub 2008 Aug 6.
4
Prognostic factors in cats with chronic kidney disease.患有慢性肾病的猫的预后因素。
J Vet Intern Med. 2007 Sep-Oct;21(5):906-16.
5
Lanthanum carbonate.
Drugs Today (Barc). 2006 Dec;42(12):759-70. doi: 10.1358/dot.2006.42.12.1025698.
6
Nutritional management of chronic renal disease in dogs and cats.犬猫慢性肾病的营养管理
Vet Clin North Am Small Anim Pract. 2006 Nov;36(6):1377-84, viii. doi: 10.1016/j.cvsm.2006.08.011.
7
Katkor cat litter, a non-invasive method of collecting cat urine for phosphate determination.
J S Afr Vet Assoc. 2005 Dec;76(4):233-4. doi: 10.4102/jsava.v76i4.433.
8
Lanthanum carbonate.碳酸镧
Ann Pharmacother. 2006 Feb;40(2):234-40. doi: 10.1345/aph.1G224. Epub 2006 Jan 31.
9
Clinical nutrition in gerontology: chronic renal disorders of the dog and cat.老年医学中的临床营养:犬猫的慢性肾脏疾病
Vet Res Commun. 2005 Aug;29 Suppl 2:57-63. doi: 10.1007/s11259-005-0012-6.
10
Retrospective study of the survival of cats with acquired chronic renal insufficiency offered different commercial diets.对接受不同商业饮食的获得性慢性肾功能不全猫的生存情况进行回顾性研究。
Vet Rec. 2005 Aug 13;157(7):185-7. doi: 10.1136/vr.157.7.185.